Huntington Study Group

Huntington Study Group company information, Employees & Contact Information

The Huntington Study Group (HSG), a not-for-profit organization founded in 1993 in Rochester, NY, and its wholly owned subsidiary, HSG Clinical Research, Inc., designs and conducts clinical trials through the world’s first and largest collaborative network of over 800 experts in Huntington’s disease at more than 130 HSG credentialed research sites worldwide. HSG is dedicated to improving the lives of people impacted by Huntington’s disease through research, education, and collaboration. For more information, visit www.huntingtonstudygroup.org.

Company Details

Employees
29
Founded
-
Address
95 Allens Creek Road, Building 1
Industry
Research Services
NAICS
Scientific Research and Development Services
Research and Development in the Physical, Engineering, and Life Sciences
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
HQ
Rochester, NY
Looking for a particular Huntington Study Group employee's phone or email?

Huntington Study Group Questions

News

Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea - PR Newswire

Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea PR Newswire

Huntington Study Group (HSG) Conference 2024 – Day 3 - HDBuzz

Huntington Study Group (HSG) Conference 2024 – Day 3 HDBuzz

Huntington Study Group (HSG) Conference 2024 – Day 1 - HDBuzz

Huntington Study Group (HSG) Conference 2024 – Day 1 HDBuzz

New Guidelines Outline How Physical Therapy Can Help People with Huntington’s Disease - Teachers College - Columbia University

New Guidelines Outline How Physical Therapy Can Help People with Huntington’s Disease Teachers College - Columbia University

Drug Helps Reduce Involuntary Movements for People with Huntington Disease - University of Rochester Medical Center

Drug Helps Reduce Involuntary Movements for People with Huntington Disease University of Rochester Medical Center

Neurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Study Group 2023 - PR Newswire

Neurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Study Group 2023 PR Newswire

Neuroscience Institute Joins Study of Huntington's Disease Patients and Their Families - University of Cincinnati

Neuroscience Institute Joins Study of Huntington's Disease Patients and Their Families University of Cincinnati

Valbenazine receives FDA approval for chorea associated with Huntington's disease - Medical Dialogues

Valbenazine receives FDA approval for chorea associated with Huntington's disease Medical Dialogues

Take a Little Trip: The rich imagination and wave pool art of Phil Roberts - Wave Pool Mag

Take a Little Trip: The rich imagination and wave pool art of Phil Roberts Wave Pool Mag

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules - PR Newswire

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules PR Newswire

Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology - PR Newswire

Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology PR Newswire

Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease - PR Newswire

Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease PR Newswire

Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease - PR Newswire

Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease PR Newswire

Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use - PR Newswire

Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use PR Newswire

Top Huntington Study Group Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant